Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Rush University Medical Center
Conditions and Treatments
Search by Topic or Doctor's Name
At the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.
— Octavio Vega, MD, internist
I enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.
— Patricia Graham, MD, internist
Hear more from doctors at Rush.
Directions and Parking
Health and Wellness
Health News and Advice to Fit Your Life
The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.
5 Things You Can Do to Prevent CancerHow you can devise a cancer prevention action plan.
Combating Social Media DysmorphiaHow to love yourself — and your selfies — without filters or fillers.
About RushThe Rush SystemPatient StoriesNational Recognition and AccreditationsRush News
Quality and Safety at RushPatient Satisfaction and FeedbackRush in the CommunityDiversity and Inclusion
Disability Rights and AccommodationsCommitment to LGBTQ Health CareVolunteeringBondholder Information
Descartes-11 in relapsed or refractory multiple myeloma.
Ibrutinib and obinutuzumab with or without venetoclax in treating older patients with untreated chronic lymphocytic leukemia.
Ibrutinib and obinutuzumab with or without venetoclax in treating patients with chronic lymphocytic leukemia.
Clinical trial with combination therapies in AML with FLT3 mutation in patients not eligible for intensive induction chemotherapy.
A phase 3 multicenter, randomized, placebo-controlled study to determine the effect of topical SGX301 and fluorescent bulb-light irradiation for the treatment of cutaneous T-cell lymphoma.
A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype.
A phase 2 study of the combination of ublituximab + TGR-1202 and TG-1202 alone in patients with previously treated diffuse large B-cell lymphoma.
Safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients with hemophilia A.
Randomized phase II/III study of venetoclax (ABT199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double expressing lymphomas.
Study of ME-401 in subjects with follicular lymphoma after failure of two or more prior therapies.